Get the Stockscreener App
1.55
2.52%
-0.04
Cellectis Adr stock is traded at $1.55, with a volume of 29,302.
It is down -2.52% in the last 24 hours and down -26.19% over the past month.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
See More
Previous Close:
$1.59
Open:
$1.6
24h Volume:
29,302
Relative Volume:
0.21
Market Cap:
$159.15M
Revenue:
$5.15M
Net Income/Loss:
$-65.35M
P/E Ratio:
-1.1481
EPS:
-1.35
Net Cash Flow:
$-20.85M
1W Performance:
-3.73%
1M Performance:
-26.19%
6M Performance:
-24.76%
1Y Performance:
-48.50%
1-Day Range:
$1.55
$1.6347
1-Week Range:
$1.51
$1.70
52-Week Range:
$1.41
$3.38
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
1.57 | 159.15M | 5.15M | -65.35M | -20.85M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.89 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.97 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| May-18-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-06-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-08-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-28-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-16-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Robert W. Baird | Outperform |
| Mar-06-20 | Downgrade | Goldman | Neutral → Sell |
| Oct-30-19 | Resumed | Guggenheim | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| May-24-19 | Resumed | Citigroup | Neutral |
| Mar-14-19 | Initiated | William Blair | Outperform |
| Dec-19-18 | Initiated | Goldman | Neutral |
| Jul-16-18 | Initiated | Barclays | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Sep-05-17 | Downgrade | SunTrust | Buy → Hold |
| Sep-05-17 | Reiterated | Wells Fargo | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Feb-28-17 | Initiated | Wells Fargo | Outperform |
| Apr-05-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Jul-20-15 | Initiated | BofA/Merrill | Buy |
| Apr-20-15 | Initiated | Jefferies | Buy |
| Apr-20-15 | Initiated | Piper Jaffray | Overweight |
View All
Cellectis Adr Stock (CLLS) Latest News
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer - GlobeNewswire Inc.
This Penny Stock Has 270% Upside Potential In 2025. Is It A Buy Now? - Barchart
Analysts Predict 400% Upside Potential for This Penny Stock - Yahoo Finance
Cellectis stock plunges to 52-week low at $1.52 amid market challenges - Investing.com India
Cellectis stock touches 52-week low at $1.7 amid market challenges - Investing.com
Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year - Investing.com India
Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year ahead - Investing.com
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
Cellectis's SWOT analysis: gene-editing firm's stock faces pivotal year ahead - Investing.com
Cellectis stock touches 52-week low at $1.75 amid market challenges - Investing.com
Earnings call: Cellectis reports robust cash reserves, new R&D initiatives - Investing.com
Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com
Cellectis earnings missed by $0.03, revenue topped estimates By Investing.com - Investing.com South Africa
Cellectis earnings missed by $0.03, revenue topped estimates - Investing.com
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 - Yahoo Finance
Cellectis stock touches 52-week low at $1.77 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remains Down for Week - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges - Investing.com
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges By Investing.com - Investing.com South Africa
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By Investing.com - Investing.com
AstraZeneca completes equity investment agreement with Cellectis - AstraZeneca
CellectisADR (CLLS) Price Target Increased by 20.85% to 11.75 - MSN
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions - AstraZeneca
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature.com
Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger - Equities News
Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U
Current Cathie Wood Portfolio 2020: Ark Invest Holdings - New Trader U
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Yahoo Finance
7 Gene Editing Companies Investors Should Watch - Nanalyze
AZN Stock Price and Chart — LSE:AZN - TradingView
New Strong Buy Stocks for October 27th - Nasdaq
Cellectis Adr Stock (CLLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):